null

null

null

null

null

null

null

null

null

null

null

null

null

Moderate-to-high leverage; Biohaven carries ~$500M+ in debt from spin-off/pipeline financing, with net debt/EBITDA negative given pre-profitability stage; a 20bp rate rise adds ~$1M+ annual interest expense.

High sensitivity; variable-rate debt tranches mean 20bp increase adds meaningful cash burn on ~$500M debt load for a company not yet EBITDA-positive, tightening runway by ~1-2 months.

Low intensity; China and India supply >60% of global API inputs, creating concentration risk.

API manufacturing via CMOs in China/India (active pharmaceutical ingredients); regulatory chokepoints at FDA/EMA for clinical-stage compounds represent top two geopolitical supply risks.

Early-stage international exposure; primary revenue currently US-centric; EUR and GBP devaluation risk modest given limited ex-US commercial sales; currency hedging not yet material.

Predominantly US-based revenue and operations; limited ex-US commercial presence; EU and UK markets targeted for future expansion; sovereign currency devaluation exposure currently low.

Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.

High dependency on single-source CMOs for troriluzole and mzanidine synthesis; no single vendor >30% by disclosed spend, but switching costs are high given regulatory filing requirements.

Clinical-stage biopharma; cloud disruption risk is moderate — clinical data, trial management, and regulatory submissions could be disrupted but CROs and backup systems provide partial redundancy.

Secondary reliance on SaaS platforms for ERP, CTMS, and data management; 30-day termination would disrupt operations but is survivable via emergency migration within 60-90 days.

Moderate API coupling risk; reliance on third-party CRO and CTMS platforms creates switching friction, but no single proprietary API lock-in; migration feasible within one trial cycle.

Low Howey Test risk; revenue model is pharmaceutical product licensing and sales, not investment contracts; no token issuance or profit-sharing scheme that triggers securities classification.

Very High

Moderate GDPR/CCPA exposure; clinical trial data from EU subjects requires DPA compliance; patient data handling in US trials triggers CCPA; current compliance infrastructure appears standard for biopharma.

Low antitrust risk currently; pipeline-stage company without dominant market share; future orphan drug exclusivity and patent protection are standard pharma mechanisms, not antitrust triggers.

Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.

Predominantly transactional/milestone-based; revenue from licensing milestones and potential product sales; no meaningful recurring subscription revenue; ~90%+ transactional or non-recurring.

Drug licensing milestones, royalties, and eventual product sales (troriluzole, CGRP franchise spin-off to Pfizer); future revenue dependent on FDA approvals and commercial launch.

Specialty pharma pricing model; pricing benchmarked against CGRP class competitors; stress-test reveals vulnerability to payer formulary exclusion and CMS negotiation pressure post-IRA.

Moderate pricing power; novel mechanisms in rare neurological diseases command premium, but competitive CGRP market and payer pushback limit absolute pricing authority; rated 6/10.

Target gross margin 70-85% at commercial scale, consistent with specialty pharma peers; currently negative given pre-revenue clinical stage and high COGS from CMO manufacturing.

No free-rider leakage problem applicable; pharmaceutical model has no subscription or platform dynamic; patient adherence and payer coverage are analogous churn risks, moderate severity.

Sublinear growth model expected at commercial stage; R&D headcount-heavy now, but commercialization can leverage contract sales forces; doubling revenue should not require doubling headcount.

Marginal cost of revenue growth declines post-approval; manufacturing scale-up via CMO contracts is variable cost; fixed R&D overhead spread over larger revenue base improves unit economics significantly.

null

At 10x scale, CAC improves via established payer contracts and physician familiarity; key constraint is managed care access and reimbursement breadth, not sales force size.

No meaningful network effects; pharmaceutical products do not exhibit traditional network effect dynamics; physician adoption and clinical evidence accumulation provide modest compounding but not true network effects.

-163.3% Return on Assets (Negative equity)

Moderate recession resistance; rare neurological disease treatments have inelastic demand among diagnosed patients, but diagnosis rates and new patient starts may slow in economic downturns.

Neurologists and movement disorder specialists (prescribers) for SCA and ALS indications; concentration risk moderate as specialist physician base is small (~3,000-5,000 relevant US neurologists.

Specialty pharmacy distributors and PBMs as channel customers; high concentration risk — top 3 specialty pharmacies control ~80% of rare disease drug distribution in the US.

["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]

0.32 (HIL — ~32% of characteristic roles agent-automatable)

Capital allocation skewed toward R&D pipeline investment rather than legacy infrastructure; no material legacy operations; CapEx is low relative to OpEx, consistent with asset-light CMO manufacturing model.

0001935979

BHVN